Previous studies have generally relied on laboratory-generated "recombinant" HBsAg mutants to evaluate the detection performance of commercial HBsAg assays. 6, 19, 20 However, a major shortcoming of the use of recombinant HBsAg mutants in this setting is that the resulting proteins do not necessarily reflect the complete and complex biostructure of the mutated HBsAg protein as it occurs in vivo in chronically HBV-infected patients. Moreover, 
| MATERIAL S AND ME THODS

| Study population
| Phylogenetic analysis
The raw sequencing output was processed by an integrated variant calling pipeline. First, the files were demultiplexed to assign the reads to the corresponding samples. Each sequencing read was then checked for sufficient length (250 bp), and primers and adapters were removed. Following this, reads were clustered using the UCHIME algorithm and the consensus sequence was assigned to the correct main type and subtype (Table 1) . Genotypes with at least 100 reads and a Phred quality score >20 on both strands were subjected to variant calling in which we kept variants with an allele frequency >5%. Each identified variant was reported to the user in a summary table.
| HBsAg assays
All 1553 patient samples were tested as singletons using the fully (Table 2) were used for the interpretation of the results of the four HBsAg qualitative assays.
| Statistics
Statistical analysis was independently performed at the AIT Austrian
Institute of Technology (Vienna, Austria) in a multistep approach including data preprocessing, formatting, calculation and evaluation.
For this, Python (version 2.7.6) scripts and the scientific computing module NumPy were used. Graphical visualizations were created using the matplotlib package.
| RE SULTS
We 
| Performance of commercial HBsAg assays
In this global cohort (n = 1553 samples), sensitivity of the Elecsys samples generated discrepant results (detectable by one assay but not another) in all four commercial HBsAg assays. Whereas four of these carried mutations in the "a" determinant region, six did not exhibit any mutations in the MHR (Table 4) . Unlike the three other as- 
| D ISCUSS I ON
This is the first report to assess the detection rates of in vivo HBsAg mutations in four major clinically relevant screening assays using a In our previous study, we noted a considerably higher mutation frequency (72%) in the MHR than previously reported. laboratories. [42] [43] [44] Additionally, as demonstrated in our previous study, the "a" determinant region mutations in native samples are complex, with sample-to-sample mutation rates varying between 5% and 100%. 21 Some of the comparator assays were assumed to be effective for mutant detection based on the use of recombinant proteins; however, our study relying on native HBV samples suggests that such studies do not necessarily reflect the bona fide in vivo situation. 25, 45 In summary, the results of this large-scale global cohort study indicate that the Elecsys ® HBsAg II Qual assay exhibits the highest sensitivity among the commercial HBsAg screening assays, which all performed well for the detection of HBV infection. Based on the results from a large number of sequenced native samples, including 345 different types of HBsAg mutation, we conclude that the capacity of the Elecsys ® HBsAg II Qual assay to detect HBV infection is not compromised by HBsAg MHR mutants.
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